Clinical Updates & Insights

Prognostic genetic testing is recommended for all patients with chronic lymphocytic leukemia (CLL). However, recent research shows that testing is infrequently performed and outcomes poorer in patients with unfavorable disease risk.

Unlike the clinical management of other types of cancer, a multidisciplinary approach is not the established norm for treating skin cancer, resulting in significantly limited opportunities to individualize patient care.

Spinal cord compression due to spinal metastases is a medical emergency. Modern treatment approaches have fundamentally shifted the paradigm from providing short-term palliation and pain relief to delivering durable tumor control with fewer morbidities than older approaches. Therefore, cancer patients who have symptoms of spinal cord compression should be referred for surgical evaluation as soon as possible.

The preliminary results of our ongoing trial investigating CAR T cell therapy to treat patients with malignant pleural disease, including mesothelioma, show “encouraging clinical outcomes”

Lymphoma experts Anas Younes, MD and Andrew Zelenetz, MD, PhD discuss the fast evolving research on CAR T cells and checkpoint inhibitors that is yielding the novel treatment options improving both outcomes and quality of life for people with lymphoma.

Topical minoxidil can be of significant benefit to women with breast cancer who develop alopecia during treatment with endocrine therapies, our most recent research shows.

Across the United States, there is a disparity in the rate of people who are candidates for a partial nephrectomy — those with small renal tumors — and those who actually have the procedure.

Emerging evidence shows that immediate autologous breast reconstruction can tolerate radiotherapy better than previously thought in select cases.

The incidence of colorectal cancer in those under the age of 50 has been increasing globally at an alarming rate. Pinpointing the reason remains elusive. Memorial Sloan Kettering has just opened the first center in the world dedicated to research and treatment of the disease as it presents in this demographic.

Despite significant advances in supportive care and improvements in allogeneic hematopoietic stem cell transplantationoutcomes, about one in every three patients succumbs to post-transplant toxicities, half of which are not related to graft-versus-host disease.